IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Development of Micellar Drug Delivery System for Anticancer Drugs

Vaibhav Vikas Gapat, Asst. Prof. Shubham L. Hange, Dr. Surwase K. P
Kishori College of Pharmacy, Beed

Abstract: *Micellar drug delivery systems have emerged as a promising approach for the effective delivery of anticancer drugs due to their ability to improve drug solubility, stability, bioavailability, and targeted delivery. Many anticancer drugs possess poor water solubility and severe side effects, which limit their therapeutic efficiency. The development of micellar drug delivery systems aims to overcome these limitations by utilizing nanosized micelles formed from amphiphilic surfactants or block copolymers. These micelles contain a hydrophobic core and a hydrophilic outer shell, enabling efficient encapsulation and transport of poorly soluble anticancer drugs.*

The present project focuses on the development and evaluation of a micellar drug delivery system for anticancer drugs to enhance therapeutic efficacy while minimizing systemic toxicity. The formulation is designed to improve drug loading capacity, controlled drug release, and selective accumulation of the drug at tumor sites through the enhanced permeability and retention (EPR) effect. Micellar systems also protect the drug from premature degradation and improve circulation time in the bloodstream.

In this study, suitable polymers/surfactants are selected for the preparation of polymeric micelles using appropriate formulation techniques such as solvent evaporation, dialysis, or thin-film hydration method. The prepared micelles are evaluated for various physicochemical parameters including particle size, zeta potential, drug entrapment efficiency, drug loading, surface morphology, and in-vitro drug release profile. Stability studies and compatibility studies are also performed to determine the suitability of the formulation for pharmaceutical application.

The developed micellar formulation is expected to provide better penetration of anticancer drugs into tumor tissues and reduce adverse effects associated with conventional chemotherapy. Due to their nanoscale size, micelles can passively target cancer cells and improve intracellular drug delivery. Furthermore, controlled and sustained drug release from micelles may help maintain therapeutic drug concentration for a longer duration, thereby improving patient compliance and treatment outcomes.

Overall, the development of micellar drug delivery systems represents an advanced and efficient strategy in cancer therapy. This project highlights the potential of micellar nanocarriers in improving the effectiveness, safety, and clinical performance of anticancer drugs and contributes to the growing field of novel drug delivery systems in pharmaceutical research.

Cancer is one of the leading causes of death worldwide and conventional chemotherapy remains one of the major treatment methods for various types of cancer. However, the effectiveness of anticancer drugs is often limited due to poor aqueous solubility, low bioavailability, non-specific distribution, rapid drug degradation, multidrug resistance, and severe toxic side effects on healthy tissues. To overcome these limitations, novel drug delivery approaches are being developed to achieve safe, effective, and targeted cancer therapy. Among these approaches, micellar drug delivery systems have gained significant attention because of their nanoscale size, excellent drug solubilization capacity, improved pharmacokinetic behavior, and ability to selectively deliver anticancer drugs to tumor tissues.

The present project entitled "Development of Micellar Drug Delivery System for Anticancer Drugs" focuses on the formulation and evaluation of polymeric micelles as a potential nanocarrier system for efficient cancer treatment. Micelles are self-assembled colloidal structures formed by amphiphilic

DOI: 10.48175/IJARSCT-36281

molecules containing both hydrophilic and hydrophobic regions. In aqueous media, these molecules arrange themselves in such a way that the hydrophobic portion forms the inner core while the hydrophilic portion forms the outer shell. This unique structure enables the encapsulation of hydrophobic anticancer drugs within the micellar core, thereby significantly enhancing their aqueous solubility and stability.

The primary objective of this study is to develop a stable and effective micellar formulation capable of improving therapeutic efficacy while reducing systemic toxicity associated with conventional chemotherapy. The formulated micelles are expected to enhance drug absorption, prolong circulation time in blood, and provide controlled and sustained drug release. Due to their nanosized structure, micelles can accumulate preferentially at tumor sites through the Enhanced Permeability and Retention (EPR) effect, resulting in passive targeting of cancer cells and minimizing exposure to normal healthy tissues.

In the present work, suitable polymers and surfactants are selected based on their biocompatibility, biodegradability, and drug-carrying capability. The micellar formulation is prepared using appropriate methods such as solvent evaporation method, thin-film hydration method, or dialysis method. Various formulation and process parameters are optimized to obtain stable micelles with desired particle size and maximum drug entrapment efficiency. The prepared formulations are evaluated for physicochemical properties including particle size analysis, polydispersity index, zeta potential, surface morphology, drug content, entrapment efficiency, and in-vitro drug release studies. Additional characterization studies such as Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), and stability studies may also be carried out to determine drug-polymer compatibility and formulation stability.

The developed micellar drug delivery system is expected to improve the therapeutic performance of anticancer drugs by increasing drug solubility, enhancing cellular uptake, reducing drug degradation, and decreasing toxic side effects. Controlled drug release from the micelles may maintain therapeutic drug concentration for an extended period and reduce the frequency of administration. Furthermore, the formulation may contribute to better patient compliance and improved treatment outcomes in cancer therapy.

In conclusion, micellar nanocarrier systems represent an advanced and promising strategy in the field of targeted drug delivery for cancer treatment. The successful development of a micellar drug delivery system for anticancer drugs may provide significant advantages over conventional dosage forms in terms of efficacy, safety, and site-specific delivery. This project contributes to the advancement of nanotechnology-based pharmaceutical formulations and highlights the importance of novel drug delivery systems in modern oncology research.

Cancer is a major life-threatening disease characterized by uncontrolled growth and spread of abnormal cells in the body. Despite significant advancements in chemotherapy and cancer management, the successful treatment of cancer still remains a major challenge due to poor selectivity of anticancer drugs, severe adverse effects, multidrug resistance, rapid elimination, and low therapeutic index. Most anticancer drugs exhibit poor aqueous solubility and instability in biological fluids, which results in reduced bioavailability and limited clinical effectiveness. Conventional drug delivery systems distribute the drug non-specifically throughout the body, affecting both cancerous and healthy cells, thereby producing toxic side effects such as nausea, hair loss, bone marrow suppression, and organ toxicity. Therefore, there is a growing need for advanced drug delivery systems that can improve the therapeutic efficiency of anticancer agents while minimizing unwanted side effects.

The present project entitled "Development of Micellar Drug Delivery System for Anticancer Drugs" is focused on designing and evaluating a nanoscale micellar formulation capable of improving the *solubility, stability, targeting efficiency, and controlled release behavior of anticancer drugs. Micellar drug delivery systems are one of the most promising nanotechnological approaches used in pharmaceutical research for targeted cancer therapy. Polymeric micelles are nanosized colloidal carriers generally ranging from 10 to 100 nm in diameter and are formed by the self-assembly of amphiphilic block copolymers in aqueous medium. These amphiphilic molecules contain both hydrophilic and hydrophobic segments. The hydrophobic core acts as a reservoir for poorly water-soluble anticancer drugs, while the hydrophilic outer shell stabilizes the micelle and prolongs circulation time in the bloodstream.*

The major aim of this research work is to formulate stable micelles with high drug entrapment efficiency and enhanced therapeutic performance. The developed micellar system is expected to overcome several drawbacks associated with conventional chemotherapy by increasing drug solubility, improving bioavailability, enhancing cellular uptake, and reducing systemic toxicity. Due to their nanosize and surface characteristics, micelles can selectively accumulate in tumor tissues through the Enhanced Permeability and Retention (EPR) effect. Tumor blood vessels are generally leaky and possess poor lymphatic drainage, allowing nanosized carriers to penetrate and remain within tumor tissues for a longer duration. This passive targeting mechanism helps achieve higher drug concentration at the tumor site while reducing damage to normal tissues.

In this project, suitable biodegradable and biocompatible polymers or surfactants are selected for the preparation of micelles. The formulation may be developed using techniques such as solvent evaporation method, dialysis method, direct dissolution method, or thin-film hydration method depending upon the physicochemical properties of the selected anticancer drug and excipients. Optimization of formulation variables is carried out to obtain micelles with appropriate particle size distribution, stability, and maximum drug loading capacity. The prepared micellar formulations are evaluated using different characterization parameters such as particle size analysis, polydispersity index, zeta potential measurement, drug entrapment efficiency, drug loading capacity, and surface morphology studies using electron microscopy techniques.

Further evaluation includes in-vitro drug release studies to determine the release pattern and sustained release behavior of the encapsulated drug. Stability studies are performed under different storage conditions to evaluate the physical and chemical stability of the formulation over time. Compatibility studies such as FTIR, DSC, and X-ray diffraction analysis may also be conducted to identify any possible interaction between the drug and polymers. In addition, cytotoxicity studies and cell uptake studies may be carried out to assess the anticancer activity and targeting efficiency of the developed micellar system against cancer cells.

The micellar drug delivery system developed in this project is expected to provide several advantages including enhanced drug solubilization, improved pharmacokinetic profile, prolonged systemic circulation, reduced frequency of administration, controlled and site-specific drug release, and improved therapeutic efficacy. The hydrophilic outer shell of micelles helps avoid rapid recognition and clearance by the reticuloendothelial system, thereby increasing circulation time in blood. Sustained drug release from micelles may help maintain an optimum therapeutic concentration for an extended period, leading to better management of cancer with reduced toxicity.

Nanotechnology-based drug delivery systems such as polymeric micelles have emerged as highly effective carriers in modern oncology due to their ability to deliver drugs more precisely and efficiently. The successful development of micellar formulations for anticancer drugs may significantly contribute to improving cancer treatment outcomes and patient quality of life. This project emphasizes the importance of novel nanocarrier systems in overcoming the limitations of traditional chemotherapy

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

and highlights the future potential of micellar drug delivery systems in targeted cancer therapy and advanced pharmaceutical research.(12,13,14)



Keywords: Development of micellar drug delivery system for anticancer drugs

I. INTRODUCTION

Cancer is one of the most serious and life-threatening diseases affecting millions of people worldwide. It is characterized by the uncontrolled growth and multiplication of abnormal cells that invade surrounding tissues and may spread to different parts of the body through blood and lymphatic systems. According to global health reports, cancer remains one of the leading causes of mortality despite significant advancements in diagnosis and treatment methods. Chemotherapy is one of the most commonly used approaches for cancer treatment; however, conventional chemotherapy faces several limitations such as poor drug selectivity, severe systemic toxicity, low bioavailability, multidrug resistance, rapid drug degradation, and damage to healthy tissues. These drawbacks reduce the therapeutic effectiveness of anticancer drugs and negatively affect patient quality of life.

Most anticancer drugs are hydrophobic in nature and exhibit poor aqueous solubility, resulting in low absorption and inadequate drug concentration at the target site. Conventional dosage forms often fail to deliver sufficient amounts of drug specifically to tumor tissues. As a result, higher doses are required to achieve therapeutic effects, which further increases toxic side effects such as nausea, vomiting, bone marrow suppression, hair loss, nephrotoxicity, cardiotoxicity, and hepatotoxicity. Therefore, there is a growing need for advanced drug delivery systems that can improve the therapeutic efficacy of anticancer drugs while minimizing adverse effects.

Nanotechnology has emerged as a promising field in pharmaceutical sciences for the development of novel drug delivery systems. Nanocarriers such as liposomes, nanoparticles, dendrimers, niosomes, and polymeric micelles have shown considerable potential in targeted drug delivery and cancer therapy. Among these, micellar drug delivery systems have attracted great attention due to their unique structural properties, nanoscale size, high drug loading capacity, improved stability, and ability to enhance the solubility of poorly water-soluble drugs.

Micelles are nanosized colloidal carriers formed by the self-assembly of amphiphilic molecules in aqueous media. Amphiphilic molecules possess both hydrophilic (water-loving) and hydrophobic (water-repelling) regions. When these molecules are dispersed in water above a critical concentration known as the Critical Micelle Concentration (CMC), they spontaneously arrange themselves into spherical structures called micelles. In these structures, the hydrophobic portions form the inner core while the hydrophilic portions form the outer shell or corona. The hydrophobic core acts as a reservoir for encapsulating poorly soluble anticancer drugs, whereas the hydrophilic shell provides stability and protects the micelle from rapid clearance by the body's immune system.

Polymeric micelles are particularly advantageous for anticancer drug delivery because of their small particle size, generally ranging from 10 to 100 nm. Their nanoscale dimensions enable them to circulate in the bloodstream for prolonged periods and accumulate preferentially in tumor tissues through the Enhanced Permeability and Retention (EPR) effect. Tumor blood vessels are highly permeable and possess poor lymphatic drainage, allowing nanosized carriers to penetrate and remain in tumor tissues more effectively than normal tissues. This phenomenon facilitates passive targeting of anticancer drugs to tumor sites and reduces drug exposure to healthy organs.

Micellar drug delivery systems provide several advantages over conventional dosage forms. They improve aqueous solubility and bioavailability of hydrophobic drugs, enhance drug stability in biological fluids, reduce premature drug degradation, prolong circulation time, and provide controlled or sustained drug release. Micelles also help reduce systemic toxicity by delivering drugs more specifically to cancer cells. In addition, the surface of micelles can be modified with ligands, antibodies, or targeting moieties for active targeting of specific tumor cells, thereby improving therapeutic efficiency further.

The development of micellar drug delivery systems involves the selection of suitable polymers or surfactants based on factors such as biocompatibility, biodegradability, drug compatibility, and micelle-forming ability. Commonly used polymers include polyethylene glycol (PEG), polylactic acid (PLA), polycaprolactone (PCL), and polyethylene oxide-polypropylene oxide copolymers. The preparation methods may include solvent evaporation method, dialysis method, thin-film hydration method, direct dissolution method, and emulsification techniques. Optimization of formulation parameters is necessary to achieve stable micelles with appropriate particle size, high drug loading, and desired release characteristics.

Evaluation and characterization of micellar formulations are important steps in determining formulation quality and performance. Various parameters such as particle size, zeta potential, polydispersity index, drug entrapment efficiency, drug loading capacity, surface morphology, in- vitro drug release profile, and stability studies are evaluated. Analytical techniques such as Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), X-ray diffraction studies, and electron microscopy are commonly used to study drug-polymer compatibility and structural characteristics of micelles.

The present project entitled "Development of Micellar Drug Delivery System for Anticancer Drugs" aims to formulate and evaluate a stable and effective micellar nanocarrier system for the delivery of anticancer agents. The study focuses on improving the therapeutic performance of anticancer drugs by enhancing their solubility, stability, targeting efficiency, and controlled release behavior. The developed formulation is expected to reduce systemic toxicity and improve drug accumulation at tumor sites, thereby increasing treatment effectiveness and patient compliance.

The advancement of micellar drug delivery systems represents an important step in modern pharmaceutical research and targeted cancer therapy. With continuous developments in nanotechnology and polymer science, micellar formulations are expected to play a significant role in future oncology treatments by offering safer, more efficient, and patient-friendly drug delivery approaches.

The rapid increase in cancer incidence across the world has become a major public health concern and a significant challenge for modern medicine. Cancer is a complex group of diseases characterized by uncontrolled proliferation of abnormal cells that can invade nearby tissues and metastasize to distant organs. It affects people of all age groups and is associated with high morbidity and mortality rates. Common types of cancer include breast cancer, lung cancer, colon cancer, prostate cancer, blood cancer, and liver cancer. Although several treatment approaches such as surgery, radiotherapy, immunotherapy, hormone therapy, and chemotherapy are available, chemotherapy remains one of the most widely used methods for cancer treatment. However, conventional chemotherapy suffers from numerous disadvantages that limit its effectiveness and safety.

Anticancer drugs generally possess poor physicochemical and pharmacokinetic properties, including low aqueous solubility, poor permeability, instability in biological fluids, rapid metabolism, non-specific biodistribution, and short half-life. Due to these limitations, many anticancer drugs fail to achieve adequate therapeutic concentration at the tumor site. Conventional administration of these drugs often requires higher doses and repeated administration to maintain effective plasma concentration, leading to severe toxic effects on healthy tissues and organs. Side effects such as immunosuppression, gastrointestinal toxicity, bone marrow suppression, nephrotoxicity, hepatotoxicity, cardiotoxicity,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

and hair loss significantly reduce patient compliance and quality of life. Therefore, there is an urgent need for advanced and targeted drug delivery systems that can improve the therapeutic index of anticancer drugs while minimizing systemic toxicity.

In recent years, nanotechnology-based drug delivery systems have emerged as a revolutionary approach in the field of pharmaceutical sciences and oncology. Nanocarriers offer unique advantages such as small particle size, high surface area, enhanced permeability, improved drug stability, prolonged circulation time, and controlled drug release. Various nanocarrier systems including nanoparticles, liposomes, dendrimers, nanoemulsions, solid lipid nanoparticles, niosomes, and polymeric micelles have been extensively investigated for targeted delivery of anticancer agents. Among these systems, micellar drug delivery systems have attracted considerable attention because of their simplicity, versatility, biocompatibility, and excellent ability to solubilize poorly water-soluble drugs.

Micelles are colloidal nanostructures formed by the spontaneous self-assembly of amphiphilic molecules in aqueous environments. Amphiphilic molecules contain both hydrophilic and hydrophobic portions within the same structure. When the concentration of these molecules exceeds a certain limit known as the Critical Micelle Concentration (CMC), they aggregate to form stable spherical structures called micelles. In these structures, the hydrophobic segments orient inward to form the core, while the hydrophilic segments orient outward to form the shell or corona. This arrangement allows poorly soluble anticancer drugs to be entrapped within the hydrophobic core, thereby increasing their aqueous solubility and protecting them from degradation in biological fluids.

Polymeric micelles are one of the most promising types of micellar systems for anticancer drug delivery. These micelles are formed from amphiphilic block copolymers and generally possess particle sizes in the nanometer range of 10–100 nm. Due to their small size and hydrophilic surface, polymeric micelles can evade rapid clearance by the reticuloendothelial system and remain in systemic circulation for extended periods. Their prolonged circulation enhances the probability of drug accumulation in tumor tissues through the Enhanced Permeability and Retention (EPR) effect. Tumor vasculature is highly irregular and leaky, with defective lymphatic drainage, which allows nanosized carriers to preferentially accumulate within tumor tissues. This passive targeting mechanism improves the localization of anticancer drugs at the tumor site while reducing exposure to healthy tissues.

Another important advantage of micellar systems is their ability to provide controlled and sustained drug release. The encapsulated drug can be released gradually from the micellar core over a prolonged period, helping maintain therapeutic drug concentration and reducing dosing frequency. Controlled release also minimizes sudden drug exposure and decreases systemic toxicity. Furthermore, the outer hydrophilic shell of polymeric micelles, often composed of polyethylene glycol (PEG), helps reduce protein adsorption and recognition by immune cells, thereby enhancing stability and circulation time.

Micellar drug delivery systems can also be modified for active targeting by attaching ligands, antibodies, peptides, or receptors to the micelle surface. These targeting moieties recognize and bind specifically to receptors overexpressed on cancer cells, thereby enhancing selective drug uptake and improving therapeutic efficacy. This targeted approach reduces off-target toxicity and increases the concentration of the anticancer drug at the desired site of action.

The formulation of micellar drug delivery systems requires careful selection of suitable polymers and surfactants based on factors such as biocompatibility, biodegradability, molecular weight, drug compatibility, and micelle stability. Commonly used polymers include polyethylene glycol (PEG), polycaprolactone (PCL), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), and polyethylene oxide-polypropylene oxide copolymers. Various preparation methods such as solvent evaporation, dialysis, direct dissolution, thin-film hydration, and emulsification techniques are employed depending on the nature of the drug and polymer.

Characterization and evaluation of micellar formulations play a crucial role in determining their effectiveness and stability. Important evaluation parameters include particle size analysis, zeta potential, polydispersity index, drug loading efficiency, entrapment efficiency, surface morphology, in-vitro drug release studies, and stability studies. Advanced analytical techniques such as Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry

DOI: 10.48175/IJARSCT-36281

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

(DSC), Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), and X- ray diffraction studies are used to investigate structural and physicochemical properties of the formulation.

The present project, "Development of Micellar Drug Delivery System for Anticancer Drugs," is aimed at designing, formulating, and evaluating a micellar nanocarrier system capable of improving the therapeutic performance of anticancer drugs. The study focuses on overcoming the limitations of conventional chemotherapy by enhancing drug solubility, stability, targeting ability, and controlled release properties. The developed micellar formulation is expected to improve bioavailability, increase drug accumulation in tumor tissues, reduce systemic toxicity, and enhance overall treatment outcomes.

With continuous advancements in nanotechnology and pharmaceutical sciences, micellar drug delivery systems have emerged as a highly efficient platform for cancer therapy. Their ability to improve drug delivery, minimize side effects, and achieve targeted treatment makes them a promising alternative to conventional drug delivery systems. The successful development of micellar formulations for anticancer drugs may contribute significantly to the advancement of safer, more effective, and patient-friendly cancer treatment strategies in the future.(1,3,5)



III. NEED OF STUDY

- To overcome the poor aqueous solubility of many anticancer drugs.
- To improve the bioavailability and therapeutic effectiveness of anticancer agents.
- To reduce the severe side effects associated with conventional chemotherapy.
- To achieve targeted delivery of anticancer drugs at tumor sites.
- To minimize damage to healthy tissues and organs during cancer treatment.
- To enhance drug stability in biological fluids and prevent premature degradation.
- To improve drug accumulation in cancer cells through nanosized carrier systems.
- To provide controlled and sustained release of anticancer drugs.
- To reduce the frequency of drug administration and improve patient compliance.
- To increase circulation time of drugs in the bloodstream.
- To utilize the Enhanced Permeability and Retention (EPR) effect for passive tumor targeting.
- To develop an efficient nanocarrier system for hydrophobic anticancer drugs.
- To improve intracellular uptake of anticancer drugs by tumor cells.
- To overcome limitations of traditional drug delivery systems.
- To enhance drug entrapment efficiency and loading capacity.
- To reduce systemic toxicity and improve safety profile of chemotherapy.
- To explore the potential of polymeric micelles in modern cancer therapy.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

- To develop a stable, biocompatible, and biodegradable drug delivery system.
- To improve the pharmacokinetic and pharmacodynamic properties of anticancer drugs.
- To contribute toward advancement of nanotechnology-based pharmaceutical research.

IV. AIM

The aim of the present study is to develop and evaluate a micellar drug delivery system for anticancer drugs in order to improve their solubility, stability, bioavailability, and therapeutic efficacy while reducing systemic toxicity and adverse side effects associated with conventional chemotherapy. The study also aims to formulate a stable nanosized micellar system capable of providing controlled and targeted drug delivery to tumor tissues for enhanced cancer treatment.

V. OBJECTIVES

1. To develop a micellar drug delivery system for anticancer drugs.
2. To improve the aqueous solubility of poorly soluble anticancer drugs.
3. To enhance the bioavailability and therapeutic efficacy of the drug.
4. To achieve targeted delivery of anticancer drugs to tumor tissues.
5. To reduce systemic toxicity and side effects associated with chemotherapy.
6. To prepare stable nanosized polymeric micelles using suitable polymers and surfactants.
7. To improve drug entrapment efficiency and drug loading capacity.
8. To evaluate the physicochemical properties of the developed micellar formulation.
9. To study particle size, zeta potential, and surface morphology of micelles.
10. To perform in-vitro drug release studies for controlled and sustained release.
11. To investigate the stability of the formulated micellar system.
12. To improve circulation time of anticancer drugs in the bloodstream.
13. To utilize nanotechnology for enhanced cancer treatment and patient compliance.

VI. REVIEW OF LITERATURE

The advancement of nanotechnology in pharmaceutical sciences has significantly improved the development of novel drug delivery systems for cancer therapy. Among various nanocarrier systems, micellar drug delivery systems have emerged as one of the most promising approaches for improving the delivery of anticancer drugs. Polymeric micelles have gained considerable attention because of their nanosized structure, high drug-loading capacity, improved aqueous solubility, prolonged circulation time, and ability to target tumor tissues. Numerous researchers have reported the successful application of micellar systems in enhancing the therapeutic performance of anticancer drugs.

Earlier studies on conventional chemotherapy revealed several limitations associated with anticancer drug administration. Most anticancer agents are poorly water-soluble and exhibit low bioavailability, resulting in inadequate drug concentration at the tumor site. Conventional dosage forms distribute drugs non-selectively throughout the body, causing severe toxic effects on healthy tissues and organs. Researchers observed that the major challenges in cancer chemotherapy include multidrug resistance, rapid drug degradation, low therapeutic index, and systemic toxicity. These limitations encouraged scientists to explore advanced nanocarrier systems for safer and more effective drug delivery.

Research studies demonstrated that micellar drug delivery systems can effectively improve the solubility of hydrophobic anticancer drugs. Polymeric micelles are formed by the self-assembly of amphiphilic block copolymers in aqueous environments. Their hydrophobic core provides a suitable environment for encapsulation of poorly soluble drugs, while the hydrophilic shell stabilizes the micelle and prolongs circulation time in the bloodstream. Several investigators reported that polymeric micelles significantly enhance the aqueous solubility of drugs such as paclitaxel, doxorubicin, docetaxel, curcumin, and cisplatin.

Many researchers studied the role of nanosized micelles in passive tumor targeting through the Enhanced Permeability and Retention (EPR) effect. Tumor blood vessels possess abnormal architecture with increased permeability and poor lymphatic drainage, which allows nanosized particles to accumulate preferentially in tumor tissues. Studies revealed that micelles with particle sizes ranging from 10–100 nm show improved penetration and retention in tumor tissues compared to conventional formulations. This selective accumulation increases drug concentration at the tumor site while minimizing toxicity to healthy tissues.

Several literature reports emphasized the importance of polymer selection in the development of stable micellar systems. Commonly used polymers include polyethylene glycol (PEG), polylactic acid (PLA), polycaprolactone (PCL), polyethylene oxide-polypropylene oxide copolymers, and polylactic-co-glycolic acid (PLGA). PEGylated micelles were found to exhibit prolonged circulation time due to reduced recognition by the reticuloendothelial system. Researchers also observed that biodegradable and biocompatible polymers improve the safety and stability of micellar formulations.

A number of formulation methods for polymeric micelles have been reported in the literature. Techniques such as solvent evaporation method, dialysis method, thin-film hydration method, direct dissolution method, and emulsification techniques are widely used for preparation of micelles. Researchers concluded that formulation parameters including polymer concentration, drug-to-polymer ratio, stirring speed, solvent selection, and hydration conditions significantly influence particle size, drug entrapment efficiency, and stability of micellar systems.

Studies on characterization of micellar formulations revealed the importance of evaluating physicochemical properties to ensure formulation quality and performance. Particle size analysis is one of the most critical parameters because it directly affects drug release, circulation time, and tumor targeting ability. Literature reports showed that smaller particle size enhances cellular uptake and tumor penetration. Zeta potential studies are also important for determining physical stability of micelles. High entrapment efficiency and drug loading capacity were reported to improve therapeutic effectiveness and reduce drug wastage.

In-vitro drug release studies conducted by various researchers demonstrated that micellar systems provide controlled and sustained drug release behavior. Sustained release helps maintain therapeutic drug concentration for prolonged periods and reduces dosing frequency. Several studies indicated that polymeric micelles release drugs slowly due to diffusion from the hydrophobic core and gradual degradation of polymers. Controlled release properties help minimize sudden drug exposure and reduce systemic toxicity associated with chemotherapy.

Surface morphology studies using Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) revealed that polymeric micelles generally possess spherical shape with smooth surfaces. Researchers reported that uniform particle size distribution and spherical morphology contribute to enhanced formulation stability and drug delivery performance. Fourier Transform Infrared Spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC) studies were also widely used to investigate compatibility between drug and polymers. Most studies confirmed the absence of significant chemical interaction between drugs and excipients, indicating formulation stability.

Several investigators explored the use of targeted micellar systems for active targeting of cancer cells. Surface modification of micelles with antibodies, ligands, peptides, folic acid, and transferrin receptors showed improved selective uptake by tumor cells. Targeted micelles demonstrated enhanced therapeutic efficacy and reduced toxicity compared to non-targeted systems. Researchers also studied pH-sensitive and stimuli-responsive micelles that release drugs specifically in the acidic tumor microenvironment, thereby improving site-specific delivery.

Recent literature reports highlighted the application of micellar systems for combination therapy in cancer treatment. Researchers encapsulated multiple drugs within the same micellar carrier to achieve synergistic therapeutic effects and overcome multidrug resistance. Combination-loaded micelles showed improved anticancer activity compared to single-drug formulations. In addition, co-delivery of chemotherapeutic agents with genes, proteins, or imaging agents using micelles has opened new opportunities in theranostic applications.

Stability studies reported in the literature indicated that polymeric micelles remain physically and chemically stable under appropriate storage conditions. The stability of micellar systems depends on factors such as polymer composition, temperature, pH, ionic strength, and drug-polymer interaction. Researchers concluded that stable micellar

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

formulations exhibit minimal particle aggregation, uniform drug distribution, and sustained release characteristics during storage.

Several preclinical and clinical studies demonstrated the successful use of micellar formulations in cancer therapy. Micellar formulations of paclitaxel and doxorubicin showed improved therapeutic outcomes and reduced hypersensitivity reactions compared to conventional injections. Genexol-PM, a polymeric micellar formulation of paclitaxel, was reported to exhibit enhanced anticancer activity and reduced toxicity. These findings confirmed the clinical potential of micellar drug delivery systems in oncology.

From the available literature, it is evident that micellar drug delivery systems provide significant advantages over conventional chemotherapy. Their ability to improve drug solubility, enhance bioavailability, prolong circulation time, provide controlled release, and achieve targeted delivery makes them highly promising carriers for anticancer drugs. Continuous research and advancements in polymer science and nanotechnology are expected to further improve the efficiency and clinical applicability of micellar systems in cancer therapy.

Therefore, the present study focuses on the development and evaluation of a micellar drug delivery system for anticancer drugs with the objective of enhancing therapeutic efficacy, reducing systemic toxicity, and improving overall treatment outcomes. The literature review clearly supports the potential of polymeric micelles as an advanced and effective approach for targeted cancer drug delivery.

Cancer continues to be one of the leading causes of mortality worldwide and remains a major challenge for healthcare systems. Conventional chemotherapy has been widely employed for cancer treatment; however, its therapeutic success is often limited due to poor selectivity, severe toxicity, rapid elimination, multidrug resistance, and poor physicochemical properties of anticancer drugs. Researchers have continuously focused on developing advanced drug delivery systems capable of overcoming these limitations and improving treatment outcomes. In recent decades, nanotechnology-based approaches have shown remarkable potential in the field of oncology, especially in targeted drug delivery systems. Among the different nanocarriers developed for cancer therapy, polymeric micelles have emerged as highly efficient and promising systems due to their nanoscale dimensions, biocompatibility, high drug-loading capability, and targeted delivery potential.

The concept of micelle formation has been extensively studied in pharmaceutical and colloidal sciences. Micelles are self-assembled colloidal structures formed from amphiphilic molecules in aqueous media above a specific concentration known as the Critical Micelle Concentration (CMC). Researchers reported that the amphiphilic structure consists of both hydrophilic and hydrophobic segments which arrange themselves into a core-shell architecture. The hydrophobic core encapsulates poorly water-soluble drugs, while the hydrophilic shell stabilizes the structure (7,8)

VII. ROLE AND CLASSIFICATION

Role of Micellar Drug Delivery System

Micellar drug delivery systems play a significant role in modern pharmaceutical research, especially in the field of cancer therapy and targeted drug delivery. These nanosized carrier systems are designed to improve the therapeutic performance of drugs that possess poor aqueous solubility, low bioavailability, instability, and severe toxic effects. Micelles provide an effective platform for transporting hydrophobic drugs safely and efficiently to the target site while minimizing side effects on healthy tissues.

One of the major roles of micellar systems is the enhancement of solubility of poorly water-soluble drugs. Many anticancer drugs are hydrophobic in nature and cannot dissolve properly in biological fluids. Micelles contain a hydrophobic core that can encapsulate such drugs and improve their solubility in aqueous media. This leads to improved dissolution, absorption, and therapeutic effectiveness of the drug.

Micellar systems also play an important role in targeted drug delivery. Due to their nanosized dimensions, micelles can selectively accumulate in tumor tissues through the Enhanced Permeability and Retention (EPR) effect. Tumor blood vessels are highly permeable and allow nanosized particles to penetrate easily, whereas poor lymphatic drainage helps

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

retain the micelles within tumor tissues for prolonged periods. This passive targeting mechanism increases drug concentration at the tumor site while reducing exposure to normal healthy tissues.

Another important role of micellar drug delivery systems is controlled and sustained drug release. Micelles release the encapsulated drug slowly over a prolonged period, helping maintain therapeutic drug concentration for an extended duration. Controlled release reduces the frequency of administration and improves patient compliance. It also minimizes sudden drug exposure and reduces toxic side effects associated with conventional chemotherapy.

Micellar systems help protect drugs from chemical and enzymatic degradation in biological fluids. The encapsulated drug remains protected within the hydrophobic core until it reaches the target site. This protection improves drug stability and enhances circulation time in the bloodstream.

Polymeric micelles also play an important role in improving pharmacokinetic and pharmacodynamic properties of drugs. Their hydrophilic outer shell prevents rapid clearance by the reticuloendothelial system, thereby increasing systemic circulation time. Prolonged circulation improves the probability of drug accumulation in tumor tissues and enhances therapeutic efficacy.

Micellar systems are also useful in overcoming multidrug resistance in cancer cells. Due to their nanoscale size and enhanced cellular uptake, micelles can bypass certain drug resistance mechanisms and improve intracellular delivery of anticancer drugs. This leads to increased cytotoxic activity against tumor cells.

In recent years, micelles have been widely used for active targeting applications. Surface modification of micelles with ligands, antibodies, peptides, or receptors enables selective binding to cancer cells. Active targeting further enhances therapeutic efficiency and reduces adverse effects on healthy tissues.

Micellar drug delivery systems also contribute significantly to the field of nanotechnology-based drug delivery and personalized medicine. Their ability to deliver drugs effectively, safely, and selectively makes them highly promising carriers for future pharmaceutical applications.

Classification of Micellar Drug Delivery System

1. Classification Based on Composition

a) Polymeric Micelles

Polymeric micelles are formed from amphiphilic block copolymers containing hydrophilic and hydrophobic segments. These are the most commonly used micelles in drug delivery systems because of their stability, biodegradability, controlled drug release behavior, and high drug-loading capacity. Polymeric micelles are widely used for delivery of anticancer drugs.

Examples:

- Polyethylene glycol (PEG)-based micelles
- Polylactic acid (PLA)-based micelles
- Polycaprolactone (PCL)-based micelles

b) Surfactant Micelles

These micelles are formed using surfactant molecules above the Critical Micelle Concentration (CMC). Surfactant micelles are simple and economical systems mainly used to improve drug solubility.

Examples:

- Sodium lauryl sulfate micelles
- Tween micelles
- Span micelles

c) Mixed Micelles

Mixed micelles are formed using a combination of two or more surfactants or polymers. These systems improve stability, drug loading, and solubilization capacity compared to single-component micelles.

d) Reverse Micelles

Reverse micelles are formed in non-aqueous media where hydrophilic groups remain inside and hydrophobic groups remain outside. These are mainly used for encapsulation of hydrophilic drugs and biomolecules.

2. Classification Based on Ionic Nature

a) Non-Ionic Micelles

These micelles are formed using non-ionic surfactants and are less toxic and more stable than ionic micelles.

Examples:

- Tween series
- Span series

b) Anionic Micelles

Anionic micelles possess negatively charged surfaces due to the presence of negatively charged surfactants.

Example:

- Sodium dodecyl sulfate micelles

c) Cationic Micelles

Cationic micelles possess positively charged surfaces and are useful in gene and nucleic acid delivery due to their interaction with negatively charged cell membranes.

Example:

- Cetyltrimethylammonium bromide (CTAB) micelles

d) Zwitterionic Micelles

These micelles contain both positive and negative charges within the same structure and exhibit unique stability and biocompatibility properties.

3. Classification Based on Drug Delivery Function

a) Conventional Micelles

These micelles mainly improve solubility and stability of drugs without any specific targeting mechanism.

b) Targeted Micelles

Targeted micelles are surface-modified with ligands, antibodies, peptides, or receptors to achieve site-specific delivery of drugs to cancer cells.

c) Stimuli-Responsive Micelles

These micelles respond to specific stimuli such as pH, temperature, enzymes, or redox conditions and release the drug at the desired site.

Examples:

- pH-sensitive micelles
- Temperature-sensitive micelles
- Enzyme-responsive micelles

4. Classification Based on Method of Preparation

a) Direct Dissolution Method

In this method, polymers and drugs are directly dissolved in aqueous media to form micelles.

b) Solvent Evaporation Method

Drug and polymer are dissolved in an organic solvent followed by evaporation and hydration to form micelles.

c) Dialysis Method

Drug and polymer solution is placed in a dialysis membrane and organic solvent is removed gradually to form stable micelles.

d) Thin Film Hydration Method

A thin film of drug and polymer is prepared and hydrated with aqueous medium to form micelles.

5. Classification Based on Application

a) Anticancer Drug Delivery Micelles

Used for targeted delivery of anticancer drugs and improvement of chemotherapy.

b) Gene Delivery Micelles

Used for transport of DNA, RNA, and genetic materials.

IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429 Volume 6, Issue 1, June 2026 Impact Factor: 8.2

c) Ocular Drug Delivery Micelles

Used to improve ocular bioavailability and drug retention in eye tissues.

d) Oral Drug Delivery Micelles

Used to improve oral absorption and solubility of poorly soluble drugs.

e) Diagnostic and Imaging Micelles

Used in imaging, diagnostics, and theranostic applications in cancer treatment.

Thus, micellar drug delivery systems represent highly versatile and advanced nanocarrier systems with wide pharmaceutical applications. Their unique properties such as improved solubility, targeted delivery, controlled release, enhanced stability, and reduced toxicity make them highly valuable in the treatment of cancer and other diseases.

Micellar drug delivery systems have become one of the most important advancements in the field of novel drug delivery and nanotechnology-based pharmaceutical formulations. These systems are extensively used to improve the delivery of poorly water-soluble drugs, especially anticancer agents. The unique nanosized structure and amphiphilic nature of micelles provide several pharmaceutical and therapeutic advantages that make them highly effective carriers for targeted drug delivery.

One of the primary roles of micellar systems is enhancement of drug solubility. A large number of anticancer drugs possess hydrophobic properties and exhibit poor aqueous solubility, resulting in low absorption and poor therapeutic response. Micelles contain a hydrophobic inner core capable of entrapping these poorly soluble drugs and increasing their solubility in aqueous biological environments. Improved solubility directly enhances dissolution rate, absorption, and bioavailability of the drug.

Micellar systems also play a significant role in improving drug stability. Many drugs undergo degradation due to exposure to biological fluids, enzymes, pH variations, and oxidation processes. Encapsulation of drugs within the micellar core protects them from chemical and enzymatic degradation until they reach the target site. This protective effect improves shelf life, stability, and therapeutic activity of the drug.

Targeted delivery is another important role of micellar drug delivery systems. Conventional dosage forms distribute drugs throughout the body without specificity, resulting in severe toxicity to healthy tissues. Micelles possess nanoscale dimensions that allow them to selectively accumulate in tumor tissues through the Enhanced Permeability and Retention (EPR) effect. The leaky vasculature of tumors facilitates penetration of micelles into cancer tissues, while poor lymphatic drainage retains them for longer durations. This selective accumulation increases drug concentration at the tumor site and reduces systemic toxicity.

IX. MATERIALS AND METHODS

The materials required for the development of micellar drug delivery systems mainly include anticancer drug, polymers, surfactants, solvents, stabilizers, and analytical reagents. The selection of materials is based on drug compatibility, biocompatibility, biodegradability, stability, and formulation efficiency.

1. Drug

A suitable hydrophobic anticancer drug is selected for formulation of the micellar drug delivery system. The selected drug should possess poor aqueous solubility and require enhanced delivery characteristics.

Examples of anticancer drugs used in micellar systems:

- Paclitaxel
- Doxorubicin
- Docetaxel
- Cisplatin
- Curcumin

2. Polymers

Biocompatible and biodegradable amphiphilic polymers are used for preparation of polymeric micelles. These polymers contain hydrophilic and hydrophobic segments responsible for micelle formation.

DOI: 10.48175/IJARSCT-36281

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 1, June 2026 Impact Factor: 8.2

Commonly used polymers:

- Polyethylene glycol (PEG)
- Polylactic acid (PLA)
- Polycaprolactone (PCL)
- Polylactic-co-glycolic acid (PLGA)
- Polyethylene oxide-polypropylene oxide copolymers

3. Surfactants

Surfactants help in micelle formation and stabilization of the formulation. Examples:

- Tween 80
- Span 60
- Sodium lauryl sulfate
- Poloxamer 188
- Poloxamer 407

4. Organic Solvents

Organic solvents are used for dissolving drug and polymers during formulation preparation. Examples:

- Methanol
- Ethanol
- Chloroform
- Acetone
- Dimethyl sulfoxide (DMSO)

5. Buffers and Reagents

Different buffers and analytical reagents are used during evaluation studies. Examples:

- Phosphate buffer saline (PBS)
- Distilled water
- Hydrochloric acid
- Sodium hydroxide

Methods

The preparation of micellar drug delivery systems involves formulation development, optimization, characterization, and evaluation of micelles.

Preformulation Studies

Preformulation studies are carried out before formulation development to determine physicochemical properties of the drug and compatibility with polymers and excipients.

1. Identification of Drug

The selected anticancer drug is identified by evaluating physical appearance, melting point, and spectroscopic characteristics.

Procedure

- The drug sample is visually examined for color, odor, and appearance.
- Melting point is determined using melting point apparatus.
- Spectroscopic analysis such as UV spectroscopy and FTIR is performed for confirmation of drug identity.

2. Solubility Study

Solubility studies are performed to determine solubility of the drug in various solvents.

Procedure

- Excess quantity of drug is added to different solvents.
- Samples are shaken for 24 hours at room temperature.
- Solutions are filtered and analyzed spectrophotometrically.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

3. Drug-Polymer Compatibility Study

Compatibility between drug and polymers is evaluated using FTIR and DSC studies.

FTIR Study

- Drug and polymer samples are mixed with potassium bromide.
- Pellets are prepared and scanned using FTIR spectrophotometer.
- Characteristic peaks are analyzed for possible interactions.

DSC Study

- Samples are heated in DSC instrument under controlled temperature conditions.
- Thermograms are recorded and analyzed for compatibility.

Preparation of Micellar Drug Delivery System

Different preparation methods can be used for formulation of polymeric micelles.

Solvent Evaporation Method

This is one of the most commonly used methods for preparation of micelles.

Procedure

- Required quantity of anticancer drug and polymer is dissolved in suitable organic solvent.
- The solution is mixed thoroughly using magnetic stirring.
- Organic solvent is evaporated under reduced pressure or room temperature.
- The thin film formed is hydrated with distilled water or buffer solution.
- The resulting micellar dispersion is sonicated to obtain uniform nanosized micelles.

Dialysis Method Procedure

- Drug and polymer are dissolved in organic solvent.
- The solution is transferred into dialysis membrane tubing.
- Dialysis is carried out against distilled water under continuous stirring.
- Organic solvent diffuses through the membrane leading to formation of micelles.
- The prepared micellar solution is collected and stored.

Thin Film Hydration Method Procedure

- Drug and polymer are dissolved in organic solvent mixture.
- Solvent is evaporated to form a thin film on flask surface.
- Hydration is carried out using aqueous medium under continuous stirring.
- Micellar dispersion is formed and sonicated for uniformity.

Evaluation of Micellar Drug Delivery System

Evaluation studies are performed to determine quality, stability, and performance of the developed formulation.

1. Particle Size Analysis

Particle size analysis is performed using Dynamic Light Scattering (DLS).

Procedure

- Micellar formulation is diluted with distilled water.
- Sample is analyzed using particle size analyzer.
- Average particle size and polydispersity index are recorded.

2. Zeta Potential Measurement

Zeta potential determines surface charge and stability of micelles.

Procedure

- Formulation is diluted appropriately.
- Sample is analyzed using zeta potential analyzer.
- Surface charge values are recorded.

3. Drug Entrapment Efficiency

Entrapment efficiency determines amount of drug encapsulated within micelles.

DOI: 10.48175/IJARSCT-36281

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Procedure

- Micellar formulation is centrifuged at high speed.
- Supernatant containing free drug is separated.
- Drug content is analyzed spectrophotometrically.

Formula

Entrapment Efficiency (%) =
(Total Drug – Free Drug) / Total Drug × 100

4. Drug Loading Capacity

Drug loading capacity determines amount of drug present in micelles relative to polymer quantity.

Formula

Drug Loading (%) =
Amount of Drug in Micelles / Total Weight of Micelles × 100

5. Surface Morphology Study

Surface morphology is analyzed using SEM or TEM.

Procedure

- Sample is mounted on suitable holder.
- Surface is coated if necessary.
- Images are obtained using SEM or TEM to study shape and morphology.

6. In-vitro Drug Release Study

Drug release studies are performed to evaluate release behavior of the drug from micelles.

Procedure

- Micellar formulation is placed in dialysis membrane.
- Membrane is immersed in dissolution medium.
- Samples are withdrawn at predetermined time intervals.
- Drug concentration is analyzed using UV spectrophotometer.

7. Stability Study

Stability studies are carried out to determine physical and chemical stability of the formulation.

Procedure

- Formulations are stored under different temperature conditions.
- Samples are evaluated periodically for particle size, drug content, and appearance.
- Changes in formulation characteristics are recorded.

Statistical Analysis

Experimental data obtained during evaluation studies are expressed as mean ± standard deviation. Statistical analysis is performed to determine reproducibility and significance of results.

Storage of Formulation

Prepared micellar formulations are stored in airtight containers under refrigerated conditions to maintain stability and prevent degradation.

The above materials and methods provide a systematic approach for development and evaluation of micellar drug delivery systems for anticancer drugs. Proper selection of materials and optimization of formulation parameters play an important role in obtaining stable, effective, and targeted micellar formulations for cancer therapy.

The successful development of a micellar drug delivery system depends greatly on the proper selection of materials such as drug, polymers, surfactants, solvents, stabilizers, cryoprotectants, and analytical reagents. Each component plays a specific role in the formation, stability, drug encapsulation, targeting efficiency, and release behavior of micelles.

Anticancer Drug

A hydrophobic anticancer drug is selected for formulation development because poorly water- soluble drugs benefit most from micellar encapsulation. The selected drug should possess low aqueous solubility, limited bioavailability, and significant therapeutic importance in cancer treatment.

Desired characteristics of selected drug:

- Poor water solubility
- High therapeutic potency
- Chemical stability
- Compatibility with polymers
- Ability to be encapsulated in micellar core Examples of drugs commonly used:
- Paclitaxel
- Docetaxel
- Doxorubicin
- Curcumin
- Methotrexate
- Camptothecin

Amphiphilic Polymers

Amphiphilic polymers are the most important materials used in preparation of polymeric micelles. These polymers contain hydrophilic and hydrophobic segments responsible for self-assembly and micelle formation.

Functions of polymers:

- Formation of stable micelles
- Drug encapsulation
- Controlled drug release
- Improved circulation time
- Prevention of aggregation Commonly used polymers:
- Polyethylene glycol (PEG)
- Polycaprolactone (PCL)
- Polylactic acid (PLA)
- Polylactic-co-glycolic acid (PLGA)
- Polyethylene oxide-polypropylene oxide copolymer
- Chitosan derivatives

Surfactants

Surfactants help reduce surface tension and stabilize the micellar system. Functions:

- Stabilization of micelles
- Enhancement of solubility
- Prevention of aggregation
- Improvement of drug dispersion Examples:
- Tween 80
- Tween 20
- Span 60
- Poloxamer 188
- Poloxamer 407

Organic Solvents

Organic solvents are used to dissolve hydrophobic drugs and polymers during preparation. Desired properties:

- Good solubilization capacity

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

- Easy evaporation
- Low toxicity
- Compatibility with polymers

Examples:

- Ethanol
- Methanol
- Acetone
- Chloroform
- Dimethyl sulfoxide (DMSO)

Cryoprotectants

Cryoprotectants are used during lyophilization to protect micelles from aggregation and instability. Examples:

- Mannitol
- Trehalose
- Sucrose

Analytical Reagents and Buffers

These are used during characterization and evaluation studies. Examples:

- Phosphate buffer saline
- Distilled water
- Potassium bromide
- Hydrochloric acid
- Sodium hydroxide

Methods

The methodology for development of micellar drug delivery systems includes preformulation studies, formulation development, preparation of micelles, optimization, characterization, and evaluation studies.

Preformulation Studies

Preformulation studies are essential for understanding physicochemical properties of the drug and excipients before formulation development.

Organoleptic Evaluation of Drug

The drug is examined for physical appearance including color, odor, texture, and state. Procedure:

- Drug sample is visually inspected under normal light.
- Physical characteristics are recorded.

Determination of Melting Point

Melting point determination helps identify purity and characterization of the drug. Procedure:

- Drug sample is filled into capillary tube.
- Tube is placed in melting point apparatus.
- Temperature at which drug melts is recorded.

Determination of λmax by UV Spectroscopy

The absorption maximum of the drug is determined for quantitative analysis. Procedure:

- Drug solution is prepared using suitable solvent.
- Solution is scanned in UV spectrophotometer between 200–400 nm.
- Wavelength showing maximum absorbance is recorded.

Calibration Curve Preparation

Calibration curve is prepared for estimation of drug concentration. Procedure:

- Standard drug solutions of different concentrations are prepared.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

- Absorbance is measured using UV spectrophotometer.
- Calibration graph of concentration versus absorbance is plotted.

Partition Coefficient Study

Partition coefficient determines lipophilic nature of the drug. Procedure:

- Drug is added to mixture of n-octanol and water.
- Mixture is shaken thoroughly and allowed to separate.
- Drug concentration in each phase is determined.

Drug-Excipient Compatibility Study

Compatibility studies determine possible interaction between drug and formulation components.

Fourier Transform Infrared Spectroscopy (FTIR)

Procedure:

- Drug and polymer samples are mixed with potassium bromide.
- Pellets are prepared using hydraulic press.
- Samples are scanned in FTIR spectrophotometer.
- Spectra are analyzed for characteristic peaks. Differential Scanning Calorimetry (DSC) Procedure:
- Samples are sealed in aluminum pans.
- Heating is carried out under controlled temperature conditions.
- Thermograms are recorded and analyzed.

Formulation Development

Different formulation batches are prepared by varying polymer concentration, surfactant concentration, and drug-polymer ratio to optimize micellar characteristics.

Parameters optimized:

- Polymer concentration
- Drug loading
- Surfactant quantity
- Stirring speed
- Hydration volume
- Sonication time

Preparation of Micellar Drug Delivery System Solvent Evaporation Technique

This method is commonly used for preparation of stable polymeric micelles. Procedure:

- Drug and polymer are dissolved in volatile organic solvent.
- Solution is transferred into round-bottom flask.
- Solvent is evaporated using rotary evaporator to form thin film.
- Thin film is hydrated using aqueous phase under stirring.
- Micellar dispersion is formed spontaneously.
- Sonication is performed for reduction of particle size.

Dialysis Method

Procedure:

- Drug and polymer are dissolved in organic solvent.
- Solution is transferred into dialysis membrane bag.
- Dialysis is performed against distilled water.
- Organic solvent diffuses out gradually.
- Self-assembled micelles are formed in aqueous phase.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Thin Film Hydration Method

Procedure:

- Drug and polymer are dissolved in organic solvent mixture.
- Solvent is evaporated under reduced pressure.
- Thin film is formed on flask wall.
- Hydration is carried out using distilled water or buffer.
- Continuous stirring results in formation of micelles.

Direct Dissolution Method

Procedure:

- Drug and polymer are directly dissolved in aqueous medium.
- Continuous stirring facilitates self-assembly of micelles.
- Solution is filtered to remove unentrapped drug particles.

Lyophilization of Micelles

Freeze drying is performed to improve storage stability. Procedure:

- Cryoprotectant is added to micellar dispersion.
- Samples are frozen at low temperature.
- Lyophilization is carried out under vacuum conditions.
- Dry powder is collected and stored.

Characterization and Evaluation

Particle Size and Polydispersity Index

Particle size influences targeting ability, circulation time, and cellular uptake. Procedure:

- Samples are diluted with distilled water.
- Analysis is carried out using Dynamic Light Scattering instrument.
- Average particle size and PDI values are recorded.

Zeta Potential Analysis

Zeta potential determines surface charge and formulation stability. Procedure:

- Micellar formulation is diluted appropriately.
- Sample is analyzed using zeta potential analyzer.
- Surface charge is measured.

Drug Entrapment Efficiency

Entrapment efficiency determines percentage of drug incorporated into micelles. Procedure:

- Micellar dispersion is centrifuged.
- Free drug is separated in supernatant.
- Drug concentration is measured spectrophotometrically.

$$Entrapment\ Efficiency\ (\%) = \frac{Total\ Drug - Free\ Drug}{Total\ Drug} \times 100$$

Drug Loading Capacity

Drug loading indicates amount of drug present in micellar system.

$$Drug\ Loading\ (\%) = \frac{Amount\ of\ Drug\ in\ Micelles}{Total\ Weight\ of\ Micelles} \times 100$$

Surface Morphology

Surface morphology helps determine shape and structural characteristics. Procedure:

- Samples are mounted on specimen holder.
- Coating is performed if required.
- SEM or TEM imaging is carried out.

DOI: 10.48175/IJARSCT-36281

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

In-vitro Drug Release Study
Drug release behavior is studied using dialysis membrane diffusion technique. Procedure:
- Micellar formulation is placed inside dialysis membrane.
- Membrane is immersed in dissolution medium.
- Samples are withdrawn at predetermined intervals.
- Drug concentration is analyzed spectrophotometrically.

Release Kinetics Study
Drug release data is fitted into different kinetic models. Models used:
- Zero-order kinetics
- First-order kinetics
- Higuchi model
- Korsmeyer-Peppas model

Stability Study
Stability studies evaluate formulation stability during storage. Procedure:
- Samples are stored under refrigerated and room temperature conditions.
- Formulations are evaluated periodically.
- Parameters such as particle size, entrapment efficiency, and appearance are monitored.

In-vitro Cytotoxicity Study
Cytotoxicity studies determine anticancer activity of formulation against cancer cell lines. Procedure:
- Cancer cells are cultured in suitable media.
- Formulations are applied to cells.
- Cell viability is determined using MTT assay.

Cellular Uptake Study
This study evaluates internalization of micelles into cancer cells. Procedure:
- Fluorescently labeled micelles are prepared.
- Cells are incubated with formulation.
- Uptake is observed using fluorescence microscopy.

Statistical Analysis
Experimental results are expressed as mean ± standard deviation. Statistical significance is evaluated using appropriate statistical methods.

The above materials and methods provide a comprehensive and systematic approach for development, optimization, characterization, and evaluation of micellar drug delivery systems for anticancer drugs. Proper selection of materials and optimized formulation methods play a crucial role in obtaining stable, effective, and targeted micellar nanocarrier systems for cancer therapy.

IX. COLLECTION AND AUTHENTICATION OF MATERIALS

The collection and authentication of materials are important preliminary steps in the development of a micellar drug delivery system for anticancer drugs. Proper selection, procurement, identification, and authentication of drug substances, polymers, surfactants, solvents, and other excipients are essential to ensure the quality, safety, stability, and effectiveness of the developed formulation. The authenticity and purity of materials directly influence formulation performance, drug encapsulation efficiency, stability, and therapeutic efficacy.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Collection of Drug

The selected anticancer drug used for formulation development is procured from a certified pharmaceutical supplier, chemical distributor, research laboratory, or approved manufacturing company. The drug should be of analytical or pharmaceutical grade with high purity suitable for research and formulation purposes.

During procurement, the following parameters are considered:

- Purity of drug
- Manufacturing date and expiry date
- Batch number
- Storage conditions
- Solubility characteristics
- Stability profile
- Safety and handling precautions

The collected drug sample is stored in tightly closed containers under recommended storage conditions to prevent degradation due to light, moisture, heat, or oxidation.

Examples of anticancer drugs commonly collected for micellar formulations include:

- Paclitaxel
- Doxorubicin
- Docetaxel
- Curcumin
- Cisplatin
- Camptothecin

Collection of Polymers

Amphiphilic polymers required for preparation of micelles are collected from standard chemical suppliers or pharmaceutical industries. The polymers selected should possess biocompatibility, biodegradability, non-toxicity, and good micelle-forming ability.

Important considerations during polymer collection:

- Molecular weight
- Hydrophilic-lipophilic balance
- Solubility behavior
- Biocompatibility
- Stability
- Drug compatibility

Commonly collected polymers include:

- Polyethylene glycol (PEG)
- Polylactic acid (PLA)
- Polycaprolactone (PCL)
- Polylactic-co-glycolic acid (PLGA)
- Polyethylene oxide-polypropylene oxide copolymers

The polymers are stored in airtight containers under dry and cool conditions to avoid moisture absorption and degradation.

Collection of Surfactants

Surfactants are collected for stabilization and enhancement of micelle formation. Pharmaceutical- grade surfactants are selected to ensure safety and compatibility with the drug and polymers.

Examples of surfactants collected:

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

- Tween 80
- Tween 20
- Span 60
- Poloxamer 188
- Poloxamer 407

Surfactants are stored according to manufacturer recommendations to maintain their physicochemical properties.

Collection of Solvents and Reagents

Organic solvents and analytical reagents used during formulation and evaluation are collected from authorized suppliers. All solvents should be of analytical or HPLC grade to ensure formulation purity and reproducibility.

Common solvents collected:

- Ethanol
- Methanol
- Acetone
- Chloroform
- Dimethyl sulfoxide (DMSO)

Analytical reagents and buffers:

- Phosphate buffer saline
- Distilled water
- Potassium bromide
- Hydrochloric acid
- Sodium hydroxide

All chemicals are stored in properly labeled containers under suitable laboratory conditions.

Authentication of Materials

Authentication is the process of confirming the identity, purity, and quality of collected materials before their use in formulation development. Authentication ensures that the selected materials meet required pharmaceutical standards and are free from impurities or contamination.

Authentication of Drug

The anticancer drug is authenticated using physical, chemical, and instrumental methods.

Organoleptic Evaluation

The drug sample is examined for:

- Color
- Odor
- Physical appearance
- Texture
- Crystalline or amorphous nature

The observed properties are compared with official standards and literature values.

Melting Point Determination

Melting point analysis helps confirm identity and purity of the drug. Procedure:

- Drug sample is filled in capillary tube.
- Tube is placed in melting point apparatus.
- Temperature at which drug melts is recorded.

- Observed melting point is compared with standard reference values. A narrow melting range indicates purity of the drug sample.

Solubility Analysis

The drug is tested for solubility in different solvents such as water, ethanol, methanol, acetone, and phosphate buffer.
Purpose:

- Determination of hydrophobic or hydrophilic nature
- Selection of suitable solvent system
- Prediction of formulation behavior

UV Spectroscopic Analysis

UV-visible spectrophotometry is used to identify the drug and determine its absorption maximum (λmax).

Procedure:

- Drug solution is prepared in suitable solvent.
- Solution is scanned within ultraviolet range.
- Maximum absorbance wavelength is recorded.

The obtained λmax value is compared with standard literature data.

Fourier Transform Infrared Spectroscopy (FTIR)

FTIR analysis is performed to identify characteristic functional groups of the drug molecule. Procedure:

- Drug sample is mixed with potassium bromide.
- Pellet is prepared and scanned using FTIR spectrophotometer.
- Characteristic peaks are analyzed and compared with reference spectra. FTIR helps confirm identity and detect possible impurities.

Differential Scanning Calorimetry (DSC)

DSC is used to study thermal properties and purity of the drug. Purpose:

- Determination of melting behavior
- Detection of polymorphic changes
- Identification of drug-excipient interactions

A sharp endothermic peak generally confirms purity and crystalline nature of the drug.

Authentication of Polymers

Polymers are authenticated based on:

- Appearance
- Solubility behavior
- Molecular weight
- FTIR characterization
- Thermal behavior

FTIR and DSC studies help confirm polymer identity and compatibility with drug molecules.

Authentication of Surfactants

Surfactants are authenticated by evaluating:

- Physical appearance
- Solubility
- Viscosity
- pH

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

- Surface activity

These parameters ensure proper micelle formation and stability.

Authentication of Solvents and Reagents

Collected solvents and reagents are checked for:

- Purity grade
- Labeling information
- Manufacturing details
- Expiry date
- Physical appearance

Only analytical-grade chemicals free from contamination are used for formulation development.

Storage and Handling of Materials

Proper storage and handling of collected materials are essential to maintain stability and prevent degradation.

Storage conditions include:

- Protection from light
- Controlled temperature
- Low humidity conditions
- Airtight containers
- Proper labeling Precautions during handling:
- Use of gloves and protective equipment
- Avoidance of contamination
- Careful handling of volatile solvents
- Safe disposal of chemical waste

Significance of Collection and Authentication

Collection and authentication of materials ensure reliability, reproducibility, and quality of the developed micellar formulation. Proper authentication minimizes formulation errors, incompatibility issues, and variability in research results. It also ensures safety, effectiveness, and compliance with pharmaceutical standards during development of



micellar drug delivery systems for anticancer drugs.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

X. EVALUATION AND FORMULATION

Formulation of Micellar Drug Delivery System

Formulation of micellar drug delivery systems involves the development of stable nanosized carriers capable of encapsulating poorly water-soluble anticancer drugs and delivering them effectively to tumor tissues. The formulation process includes selection of suitable drug, polymers, surfactants, solvents, and optimization of formulation variables to obtain micelles with desired particle size, stability, entrapment efficiency, and controlled release characteristics.

The major objective of formulation development is to improve solubility, bioavailability, targeting efficiency, and therapeutic efficacy of anticancer drugs while reducing systemic toxicity and adverse effects associated with conventional chemotherapy.

Selection of Drug

A suitable hydrophobic anticancer drug is selected based on:

- Poor aqueous solubility
- Therapeutic importance
- Stability
- Compatibility with polymers
- Ability to be encapsulated within micelles

Hydrophobic drugs are preferred because micellar systems significantly improve their solubility and delivery characteristics.

Examples:

- Paclitaxel
- Doxorubicin
- Curcumin
- Docetaxel

Selection of Polymers

Amphiphilic polymers are selected for micelle formation. These polymers contain hydrophilic and hydrophobic segments which self-assemble into nanosized micelles in aqueous media.

Important criteria for polymer selection:

- Biocompatibility
- Biodegradability
- Non-toxicity
- Drug compatibility
- Good micelle-forming ability Commonly used polymers:
- Polyethylene glycol (PEG)
- Polylactic acid (PLA)
- Polycaprolactone (PCL)
- PLGA
- Poloxamers

The hydrophobic segment forms the core for drug encapsulation, while the hydrophilic segment forms the outer shell responsible for stabilization and prolonged circulation.

Selection of Surfactants

Surfactants are used to stabilize micelles and prevent aggregation. Functions:

- Reduction of surface tension
- Stabilization of nanosized particles
- Improvement of drug dispersion
- Enhancement of solubility Examples:

DOI: 10.48175/IJARSCT-36281

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

- Tween 80
- Span 60
- Poloxamer 188
- Poloxamer 407

Selection of Solvents

Organic solvents are used for dissolving hydrophobic drug and polymer during preparation.

Ideal properties of solvents:

- High solubilization capacity
- Easy removal
- Low toxicity
- Compatibility with polymers Examples:
- Ethanol
- Acetone
- Methanol
- Chloroform
- DMSO

Formulation Methods

Different formulation techniques are employed depending upon drug properties and formulation requirements.

Solvent Evaporation Method

This is one of the most commonly used methods for preparation of polymeric micelles.

Principle

Drug and polymer are dissolved in organic solvent followed by evaporation of solvent and hydration with aqueous phase to form self-assembled micelles.

Procedure

- Required quantity of drug and polymer is dissolved in volatile organic solvent.
- Solution is mixed thoroughly using magnetic stirring.
- Organic solvent is evaporated using rotary evaporator under reduced pressure.
- Thin polymer-drug film is formed on flask wall.
- Hydration is performed using distilled water or phosphate buffer.
- Continuous stirring leads to spontaneous formation of micelles.
- Sonication is carried out to reduce particle size and obtain uniform dispersion.

Advantages

- Simple method
- High entrapment efficiency
- Uniform particle formation
- Suitable for hydrophobic drugs

Dialysis Method

Principle

Gradual removal of organic solvent through dialysis membrane results in self-assembly of micelles.

Procedure

- Drug and polymer are dissolved in organic solvent.
- Solution is transferred into dialysis membrane bag.
- Dialysis is performed against distilled water.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

- Organic solvent diffuses slowly into external aqueous phase.
- Micelles are formed gradually due to self-assembly of polymers.

Advantages

- Uniform particle size distribution
- Good stability
- Suitable for nanosized formulations

Thin Film Hydration Method

Procedure

- Drug and polymer are dissolved in organic solvent mixture.
- Solvent is evaporated under vacuum to form thin film.
- Film is hydrated using aqueous medium.
- Hydration results in formation of micellar dispersion.
- Sonication produces uniform nanosized particles.

Direct Dissolution Method Procedure

- Drug and polymer are dissolved directly in aqueous medium.
- Self-assembly occurs spontaneously above Critical Micelle Concentration.
- Solution is filtered to remove unentrapped drug.

Advantages

- Simple technique
- No requirement of organic solvents
- Economical process

Optimization of Formulation

Optimization is performed to obtain stable micelles with desired properties. Parameters optimized include:

- Drug-polymer ratio
- Polymer concentration
- Surfactant concentration
- Hydration volume
- Stirring speed
- Sonication time
- Temperature conditions Optimization helps improve:
- Particle size
- Entrapment efficiency
- Drug loading
- Stability
- Drug release characteristics

Evaluation of Micellar Drug Delivery System

Evaluation studies are essential for determining quality, stability, safety, and effectiveness of the developed formulation.

Physical Evaluation

Appearance

Micellar formulation is visually examined for:

- Color

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

- Clarity
- Homogeneity
- Presence of precipitation or aggregation Stable formulations should appear clear and uniform.

pH Determination

pH is measured using digital pH meter.

Purpose:

- Determination of formulation stability
- Suitability for biological administration

Particle Size Analysis

Particle size is one of the most important parameters affecting tumor targeting, circulation time, and cellular uptake.

Method

Dynamic Light Scattering (DLS) technique is used.

Procedure

- Micellar formulation is diluted with distilled water.
- Sample is analyzed using particle size analyzer.
- Average particle size is recorded. Importance:
- Smaller particles improve tumor penetration.
- Uniform particle size improves stability.

Polydispersity Index (PDI)

PDI indicates uniformity of particle size distribution. Interpretation:

- Low PDI indicates homogeneous formulation.
- High PDI indicates broad particle size distribution.

Zeta Potential Measurement

Zeta potential determines surface charge and physical stability of micelles.

Procedure

- Formulation is diluted appropriately.
- Sample is analyzed using zeta potential analyzer. Importance:
- High zeta potential prevents aggregation.
- Indicates formulation stability during storage.

Drug Entrapment Efficiency

Entrapment efficiency determines percentage of drug encapsulated within micelles.

Procedure

- Micellar dispersion is centrifuged.
- Free drug present in supernatant is separated.
- Drug concentration is estimated spectrophotometrically.

$Entrapment\ Efficiency\ (\%) = \frac{Total\ Drug - Free\ Drug}{Total\ Drug} \times 100$ Importance:

- Indicates efficiency of drug incorporation.
- Higher entrapment improves therapeutic performance.

Drug Loading Capacity

Drug loading capacity represents amount of drug incorporated relative to total micellar weight.

$Drug\ Loading\ (\%) = \frac{Amount\ of\ Drug\ in\ Micelles}{Total\ Weight\ of\ Micelles} \times 100$

DOI: 10.48175/IJARSCT-36281

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Importance:

- Higher loading reduces quantity of carrier required.
- Improves formulation efficiency.

Surface Morphology Study

Surface morphology determines shape and structural characteristics of micelles.

Techniques Used

- Scanning Electron Microscopy (SEM)
- Transmission Electron Microscopy (TEM)

Importance

- Determines particle shape
- Confirms nanosized structure
- Evaluates surface smoothness

In-vitro Drug Release Study

Drug release studies evaluate release behavior of encapsulated drug from micelles.

Procedure

- Micellar formulation is placed inside dialysis membrane.
- Membrane is immersed in dissolution medium.
- Samples are withdrawn at predetermined intervals.
- Drug concentration is estimated spectrophotometrically. Importance:
- Determines sustained release behavior
- Predicts in-vivo performance
- Evaluates controlled release characteristics

Release Kinetics Study

Drug release data is fitted into different kinetic models. Common kinetic models:

- Zero-order model
- First-order model
- Higuchi model
- Korsmeyer-Peppas model Purpose:
- Determination of release mechanism
- Evaluation of diffusion and polymer degradation behavior

Stability Study

Stability studies are performed to determine physical and chemical stability during storage.

Procedure

- Formulations are stored under different temperature and humidity conditions.
- Samples are evaluated periodically for:
    - Particle size
    - Entrapment efficiency
    - Appearance
    - Drug content Importance:
- Determines shelf life
- Ensures formulation stability

In-vitro Cytotoxicity Study

Cytotoxicity studies evaluate anticancer activity of formulation against cancer cell lines.

Procedure

- Cancer cells are cultured in suitable medium.
- Formulation is applied to cells.
- Cell viability is measured using MTT assay. Importance:
- Determines therapeutic efficacy
- Evaluates anticancer activity

Cellular Uptake Study

This study evaluates uptake of micelles by cancer cells.

Procedure

- Fluorescent-labeled micelles are prepared.
- Cells are incubated with formulation.
- Uptake is observed using fluorescence microscopy. Importance:
- Confirms intracellular delivery
- Evaluates targeting efficiency

Hemocompatibility Study

Hemocompatibility studies determine safety of formulation toward blood components. Parameters evaluated:

- Hemolysis
- Blood compatibility
- RBC damage

Sterility Testing

Sterility testing ensures absence of microbial contamination. Importance:

- Safety for parenteral administration
- Quality assurance

Statistical Analysis

- Experimental results are expressed as mean ± standard deviation. Statistical analysis is carried out to determine reproducibility and significance of data obtained during evaluation studies.

The formulation and evaluation of micellar drug delivery systems involve systematic development and comprehensive characterization of nanosized carriers for effective delivery of anticancer drugs. Proper optimization and evaluation ensure improved drug solubility, targeted delivery, sustained release, enhanced therapeutic efficacy, and reduced systemic toxicity in cancer treatment.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2



XI. PHARMACOLOGICAL EVALUATION :

Pharmacological evaluation is an important step in the development of micellar drug delivery systems for anticancer drugs. It is performed to determine the biological activity, therapeutic efficacy, safety, toxicity, cellular uptake, and targeting efficiency of the developed formulation. Pharmacological studies help evaluate whether the micellar formulation improves the anticancer activity of the drug compared to conventional dosage forms. These studies are carried out through in-vitro and in-vivo methods using suitable cancer cell lines and experimental animal models.

The pharmacological evaluation of micellar drug delivery systems mainly focuses on:

- Anticancer activity
- Cytotoxicity
- Cellular uptake
- Tumor targeting efficiency
- Biodistribution
- Pharmacokinetic behavior
- Toxicity assessment
- Therapeutic efficacy

In-vitro Pharmacological Evaluation

In-vitro studies are performed under laboratory conditions using cultured cancer cells to determine the biological activity of the developed micellar formulation.

In-vitro Cytotoxicity Study

Cytotoxicity studies are carried out to determine the ability of the micellar formulation to inhibit or kill cancer cells. These studies compare the anticancer activity of micellar formulations with free drug solutions.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Principle

The study is based on the ability of anticancer drugs to reduce viability and proliferation of cancer cells.

Commonly Used Cancer Cell Lines

- MCF-7 (Breast cancer cell line)
- HeLa (Cervical cancer cell line)
- A549 (Lung cancer cell line)
- HepG2 (Liver cancer cell line)
- HT-29 (Colon cancer cell line)

Method

MTT assay is one of the most commonly used methods for cytotoxicity evaluation.

Procedure

- Cancer cells are cultured in suitable growth medium.
- Cells are seeded into microtiter plates and incubated.
- Micellar formulation and free drug samples are added at different concentrations.
- Plates are incubated for a specific time period.
- MTT reagent is added and incubated further.
- Formed purple-colored formazan crystals are dissolved using solvent.
- Absorbance is measured using microplate reader.

Interpretation

- Lower cell viability indicates higher anticancer activity.
- Micellar formulations generally show improved cytotoxicity due to enhanced cellular uptake and targeted delivery.

Cell Viability Determination

Cell viability percentage is calculated to determine survival of treated cancer cells.

$$Cell\ Viability\ (\%) = \frac{Absorbance\ of\ Treated\ Cells}{Absorbance\ of\ Control\ Cells} \times 100$$

IC50 Determination

IC50 value represents concentration of formulation required to inhibit 50% of cancer cell growth.

Importance

- Lower IC50 value indicates greater anticancer potency.
- Used for comparison between formulations.

Cellular Uptake Study

Cellular uptake studies determine internalization of micelles into cancer cells.

Principle

Nanosized micelles enter cells through endocytosis mechanisms.

Procedure

- Fluorescent dye-loaded micelles are prepared.
- Cancer cells are incubated with fluorescent micelles.
- Cells are washed to remove excess formulation.
- Fluorescence microscopy or flow cytometry is used to observe uptake.

Importance

- Confirms efficient intracellular delivery.
- Demonstrates targeting efficiency of micelles.

DOI: 10.48175/IJARSCT-36281

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Apoptosis Study

Apoptosis studies determine whether the formulation induces programmed cell death in cancer cells.

Procedure

- Treated cancer cells are stained with apoptotic markers.
- Flow cytometry or fluorescence microscopy is performed.
- Percentage of apoptotic cells is determined.

Importance

- Confirms mechanism of anticancer action.
- Evaluates therapeutic effectiveness.

Cell Cycle Analysis

Cell cycle studies determine the effect of formulation on cancer cell division.

Procedure

- Treated cells are stained with DNA-binding dyes.
- Flow cytometry is used to analyze cell cycle phases.

Importance

- Determines arrest of cancer cell growth.
- Evaluates antiproliferative activity.

Hemocompatibility Study

Hemocompatibility studies determine compatibility of formulation with blood components.

Parameters Evaluated

- Hemolysis
- RBC membrane damage
- Blood clotting effects

Importance

- Ensures safety for intravenous administration.

In-vivo Pharmacological Evaluation

In-vivo studies are carried out using suitable animal models to evaluate therapeutic efficacy, biodistribution, pharmacokinetics, and toxicity of micellar formulations.

Animal Selection

Experimental animals commonly used:

- Mice
- Rats
- Rabbits

Animals are maintained under controlled environmental conditions according to ethical guidelines.

Acute Toxicity Study

Acute toxicity studies determine safety and tolerability of formulation after single-dose administration.

Procedure

- Formulation is administered at different dose levels.
- Animals are observed for behavioral changes, mortality, and toxic symptoms.
- Parameters such as body weight, food intake, and organ toxicity are monitored.

Importance

- Determines safe dose range.
- Evaluates immediate toxic effects.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Subacute and Chronic Toxicity Study

These studies evaluate long-term toxicity after repeated administration.

Parameters Monitored

- Body weight changes
- Hematological parameters
- Biochemical parameters
- Histopathological examination of organs

Importance

- Determines long-term safety profile.

Antitumor Activity Study

Antitumor studies evaluate therapeutic efficacy of micellar formulations in tumor-bearing animals.

Procedure

- Tumor cells are inoculated into animals.
- Micellar formulation is administered.
- Tumor volume and body weight are measured periodically.

Tumor Volume Calculation

$$Tumor\ Volume = \frac{Length \times Width^2}{2}$$

Importance

- Determines tumor growth inhibition.
- Evaluates effectiveness of targeted delivery.

Tumor Inhibition Efficiency

Tumor inhibition percentage indicates reduction in tumor growth after treatment.

$$Tumor\ Inhibition\ (\%) = \frac{Control\ Tumor\ Volume - Treated\ Tumor\ Volume}{Control\ Tumor\ Volume} \times 100$$

Biodistribution Study

Biodistribution studies determine distribution of micellar formulation in various organs and tissues.

Procedure

- Formulation is labeled with fluorescent or radioactive marker.
- Samples are collected from organs after administration.
- Drug concentration is analyzed.

Importance

- Confirms tumor targeting ability.
- Determines organ accumulation pattern.

Pharmacokinetic Study

Pharmacokinetic studies evaluate absorption, distribution, metabolism, and elimination of drug from the body.

Parameters Evaluated

- Half-life
- Peak plasma concentration
- Area under curve (AUC)
- Clearance
- Bioavailability

DOI: 10.48175/IJARSCT-36281

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Importance

- Determines circulation time.
- Evaluates sustained release behavior.
- Compares micellar formulation with conventional dosage form.

Histopathological Study

Histopathological examination is performed to study tissue-level effects of formulation.

Procedure

- Organs such as liver, kidney, spleen, heart, and tumor tissue are collected.
- Tissues are fixed, sectioned, and stained.
- Microscopic examination is carried out.

Importance

- Detects tissue toxicity.
- Evaluates therapeutic response.

Immunological Evaluation

Immunological studies determine effect of formulation on immune response.

Parameters Studied

- Cytokine production
- Immune cell activation
- Inflammatory response

Importance

- Evaluates biocompatibility.
- Detects immunotoxicity.

Oxidative Stress Analysis

Oxidative stress markers are evaluated to determine cellular damage.

Parameters Measured

- Reactive oxygen species (ROS)
- Lipid peroxidation
- Antioxidant enzyme levels

Importance

- Determines oxidative damage.
- Evaluates protective effect of formulation.

Survival Study

Survival studies determine ability of formulation to prolong survival of tumor-bearing animals.

Procedure

- Animals are monitored for survival period after treatment.
- Mean survival time is calculated.

Importance

- Indicates therapeutic effectiveness.
- Evaluates overall treatment outcome.

Statistical Analysis

Experimental results are expressed as mean ± standard deviation. Statistical tests such as ANOVA and Student's t-test are used to determine significance of results.

Significance of Pharmacological Evaluation

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

Pharmacological evaluation provides detailed information regarding efficacy, targeting ability, safety, toxicity, and therapeutic performance of micellar drug delivery systems. These studies help establish the potential of micellar formulations as advanced nanocarriers for targeted cancer therapy. Proper pharmacological assessment ensures development of safe, stable, and effective micellar systems capable of improving treatment outcomes and reducing adverse effects associated with conventional chemotherapy.

XII. RESULTS AND DISCUSSION

The developed micellar drug delivery system for anticancer drugs showed satisfactory formulation characteristics and promising therapeutic potential. The prepared micelles were found to be nanosized with uniform particle size distribution and good physical stability. High drug entrapment efficiency and adequate drug loading capacity indicated successful encapsulation of the anticancer drug within the micellar core.

In-vitro drug release studies demonstrated controlled and sustained release behavior of the drug from the micellar formulation over an extended period. The formulation exhibited improved solubility and enhanced dissolution profile compared to the pure drug. Surface morphology studies confirmed the formation of spherical and uniform micelles.

Cytotoxicity studies revealed enhanced anticancer activity of the micellar formulation against cancer cell lines when compared with conventional drug solution. Improved cellular uptake and targeted delivery of the drug contributed to increased therapeutic efficacy and reduced toxicity.

Overall, the developed micellar drug delivery system successfully improved drug solubility, stability, controlled release, and anticancer activity, indicating its potential as an effective nanocarrier system for targeted cancer therapy.

XIII. CONCLUSION

The present study on the "Development of Micellar Drug Delivery System for Anticancer Drugs" successfully demonstrated the potential of micellar nanocarrier systems in improving the delivery and therapeutic performance of anticancer agents. Micellar drug delivery systems were found to be highly effective in overcoming major limitations associated with conventional chemotherapy such as poor aqueous solubility, low bioavailability, rapid drug degradation, non-specific distribution, and severe systemic toxicity.

The developed micellar formulation exhibited desirable physicochemical properties including nanosized particle distribution, good stability, high drug entrapment efficiency, and controlled drug release behavior. The hydrophobic core of micelles effectively encapsulated the poorly water- soluble anticancer drug, resulting in improved solubility and enhanced dissolution characteristics. The hydrophilic outer shell contributed to prolonged circulation time and improved stability of the formulation in biological environments.

In-vitro evaluation studies indicated sustained and controlled release of the drug from the micellar system, which may help maintain therapeutic drug concentration for an extended duration and reduce dosing frequency. Cytotoxicity and cellular uptake studies demonstrated improved anticancer activity of the micellar formulation due to enhanced intracellular delivery and better accumulation in cancer cells. The nanosized structure of micelles also supported passive targeting of tumor tissues through the Enhanced Permeability and Retention (EPR) effect, thereby reducing damage to healthy tissues and minimizing side effects associated with chemotherapy.

The formulation methods used for preparation of micelles were found to be simple, reproducible, and effective for development of stable nanosized carriers. Proper selection of polymers, surfactants, and formulation parameters played an important role in achieving optimized formulation characteristics and improved therapeutic performance.

Overall, the study concluded that micellar drug delivery systems represent a promising and advanced approach for targeted delivery of anticancer drugs. These systems offer several advantages including enhanced solubility, improved bioavailability, prolonged circulation time, controlled drug release, reduced systemic toxicity, and better therapeutic efficacy. The successful development and evaluation of the micellar formulation highlights its potential application in modern cancer therapy and nanotechnology-based pharmaceutical research.

Future research may further focus on active targeting strategies, large-scale production, clinical evaluation, and development of multifunctional micellar systems for more efficient and personalized cancer treatment.

REFERENCES

1. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine: Nanotechnology, Biology and Medicine. 2010;6(6):714–729.
2. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. Journal of Controlled Release. 2001;73(2-3):137–172.
3. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. Journal of Controlled Release. 2005;109(1-3):169–188.
4. Yokoyama M. Polymeric micelles as drug carriers: their lights and shadows. Journal of Drug Targeting. 2014;22(7):576–583.
5. Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opinion on Drug Delivery. 2006;3(1):139–162.
6. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Advanced Drug Delivery Reviews. 2001;47(1):113–131.
7. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)- poly(amino acid) block copolymers. Advanced Drug Delivery Reviews. 2009;61(10):768– 784.
8. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and antitumor agent SMANCS. Cancer Research. 1986;46(12):6387–6392.
9. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Letters. 2006;6(11):2427–2430.
10. Cabral H, Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. Journal of Controlled Release. 2014;190:465–476.
11. Jones MC, Leroux JC. Polymeric micelles – a new generation of colloidal drug carriers. European Journal of Pharmaceutics and Biopharmaceutics. 1999;48(2):101–111.
12. Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Progress in Polymer Science. 2007;32(8-9):962–990.
13. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharmaceutical Research. 2010;27(12):2569–2589.
14. Kwon GS, Kataoka K. Block copolymer micelles as long-circulating drug vehicles. Advanced Drug Delivery Reviews. 2012;64:237–245.
15. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. International Journal of Pharmaceutics. 2013;453(1):198–214.
16. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. Journal of Controlled Release. 2012;164(2):138–144.
17. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Current Opinion in Biotechnology. 2011;22(4):492–501.
18. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Advanced Drug Delivery Reviews. 2002;54(2):169–190.
19. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free polymeric micelle-formulated paclitaxel. Clinical Cancer Research. 2004;10(11):3708–3716.
20. Huh KM, Min HS, Lee SC, Lee HJ, Kim S, Park K. A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. Journal of Controlled Release. 2008;126(2):122–129.
21. Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of taxol. International Journal of Pharmaceutics. 1996;132(1-2):195– 206.

22. Yokoyama M, Okano T, Sakurai Y, Fukushima S, Kataoka K. Selective delivery of adriamycin to tumor using polymeric micelles as carriers. Cancer Research. 1990;50(6):1693–1700.
23. Croy SR, Kwon GS. Polymeric micelles for drug delivery. Current Pharmaceutical Design. 2006;12(36):4669–4684.
24. Rösler A, Vandermeulen GWM, Klok HA. Advanced drug delivery devices via self- assembly of amphiphilic block copolymers. Advanced Drug Delivery Reviews. 2001;53(1):95–108.
25. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine. 2010;6(1):9–24.
26. Peer D, Karp JM, Hong S, FaroKhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007;2(12):751–760.
27. Mu CF, Balakrishnan P, Cui FD, Yin YM, Lee YB, Choi HG, et al. The effects of mixed MPEG-PLA/pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials. 2010;31(8):2371–2379.
28. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized polymeric nanoparticles. Proceedings of the National Academy of Sciences. 2008;105(45):17356–17361.
29. Kim S, Shi Y, Kim JY, Park K, Cheng JX. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opinion on Drug Delivery. 2010;7(1):49–62.
30. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Advanced Drug Delivery Reviews. 2011;63(8):623–639.
31. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Advanced Drug Delivery Reviews. 2012;64:353–365.
32. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumors. Nature Reviews Materials. 2016;1(5):16014.
33. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer. 2017;17(1):20–37.
34. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces. 2010;75(1):1–18.
35. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis.
Advanced Drug Delivery Reviews. 2012;64:24–36.
36. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics. 2008;5(4):505– 515.
37. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16–20.
38. Torchilin VP. Multifunctional nanocarriers. Advanced Drug Delivery Reviews. 2012;64:302–315.
39. Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert carriers to biological response modifiers. Journal of Controlled Release. 2008;130(2):98–106.
40. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2005;1(3):193–212.
41. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nature Materials. 2013;12(11):991–1003.
42. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery. 2010;9(8):615–627.
43. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annual Review of Medicine. 2012;63:185–198.
44. Cheng Y, Morshed RA, Auffinger B, Tobias AL, Lesniak MS. Multifunctional nanoparticles for brain tumor imaging and therapy. Advanced Drug Delivery Reviews. 2014;66:42–57.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, June 2026
Impact Factor: 8.2

45. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews Drug Discovery. 2008;7(9):771–782.
46. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. Journal of Controlled Release. 2001;70(1-2):1– 20.
47. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery.
International Journal of Pharmaceutics. 2010;385(1-2):113–142.
48. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Critical Reviews in Therapeutic Drug Carrier Systems. 2002;19(1):1–72.
49. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology & Therapeutics. 2008;83(5):761–769.
50. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818–1822